Drugs that contain Febuxostat
1. Uloric patents expiration
ULORIC's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5614520 | TAKEDA PHARMS USA | 2-arylthiazole derivatives and pharmaceutical composition thereof |
Mar, 2019
(5 years ago) | |
| US6225474 | TAKEDA PHARMS USA | Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same |
Jun, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7361676 | TAKEDA PHARMS USA | Solid preparation containing single crystal form |
Mar, 2024
(a month ago) | |
| US8372872 | TAKEDA PHARMS USA | Methods for concomitant treatment of theophylline and febuxostat |
Sep, 2031
(7 years from now) | |
| US9107912 | TAKEDA PHARMS USA | Methods for concomitant treatment of theophylline and febuxostat |
Sep, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-205) | Aug 15, 2020 |
| New Chemical Entity Exclusivity(NCE) | Feb 13, 2014 |
NCE-1 date: 13 February, 2013
Market Authorisation Date: 13 February, 2009
Treatment: Use of febuxostat for the management of hyperuricemia in patients suffering from gout and, when used with theophylline without the need for dose adjustment of theophylline; Chronic management of hyper...
Dosage: TABLET;ORAL
How can I launch a generic of ULORIC before it's drug patent expiration?
More Information on Dosage
ULORIC family patents
